I really like this approach even though it's antithetical to the way medical technology is structured right now. Basically medical device companies and drug companies just want to manufacture something and hold a patent for 20 years and whatever they can get for extended.
The described approach is a lot more like programming where you have a whole bunch of skilled professionals working together to solve specific bespoke problems because cancer is actually thousands of diseases depending on the gene expression and underlying genetics.
So I really like this approach. I hope it gets formalized and scaled to some degree outside of the auspices of the drug companies who just want to patent squat
I also don't know if the FDA is equipped for it because it sounds like cuz we're going to get specifically tailored drugs or other vectors individualized but how do you test that in a way that the FDA typically does?
The described approach is a lot more like programming where you have a whole bunch of skilled professionals working together to solve specific bespoke problems because cancer is actually thousands of diseases depending on the gene expression and underlying genetics.
So I really like this approach. I hope it gets formalized and scaled to some degree outside of the auspices of the drug companies who just want to patent squat
I also don't know if the FDA is equipped for it because it sounds like cuz we're going to get specifically tailored drugs or other vectors individualized but how do you test that in a way that the FDA typically does?